<--- Back to Details
First PageDocument Content
Chemistry / Science / Evaluation methods / Pharmaceutical industry / Pharmacology / Clinical trial / Maximum tolerated dose / Phases of clinical research / Dose-ranging study / Clinical research / Design of experiments / Research
Date: 2013-07-25 21:28:57
Chemistry
Science
Evaluation methods
Pharmaceutical industry
Pharmacology
Clinical trial
Maximum tolerated dose
Phases of clinical research
Dose-ranging study
Clinical research
Design of experiments
Research

Microsoft Word - ctc-phase I and II trials.doc

Add to Reading List

Source URL: www.ctc.usyd.edu.au

Download Document from Source Website

File Size: 126,61 KB

Share Document on Facebook

Similar Documents

Amines / Drug rehabilitation / Eli Lilly and Company / Ketones / Methadone / Chemotherapy / Maximum tolerated dose / Dose / Bioavailability / Medicine / Chemistry / Organic chemistry

PDF Document

DocID: 17bs1 - View Document

Chemistry / Science / Evaluation methods / Pharmaceutical industry / Pharmacology / Clinical trial / Maximum tolerated dose / Phases of clinical research / Dose-ranging study / Clinical research / Design of experiments / Research

Microsoft Word - ctc-phase I and II trials.doc

DocID: 14er6 - View Document

Toxicology / Maximum tolerated dose / Toxicity

Full title: Dose finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method

DocID: zIK2 - View Document

Maximum tolerated dose / Toxicity / Syngenta / Toxic Substances Control Act / Sulpiride / Toxicology / Organic chemistry / Chemistry

ov ~p3 Syngenta Crop Protection, LLC P.O. Box[removed]Greensboro, NC[removed]

DocID: ybWE - View Document

Pharmaceutical sciences / Dose-ranging study / Aspirin / Toxicity / Bioavailability / Dose / Maximum tolerated dose / Toxicology / Medicine / Pharmacology

Package ‘bcrm’ July 2, 2014 Type Package Title Bayesian continual reassessment method (CRM) designs for Phase I dose-finding trials. Version[removed]Date[removed]

DocID: xoUd - View Document